What does G & PHarma do?

G & PHarma is a pharmacy in Halen. Private Limited, started on 18 January 2008, 1 establishment.

What is the address of G & PHarma?

The registered office of G & PHarma is located at Loksbergenstraat 61, 3545 Halen.

Is G & PHarma still active?

Yes. According to the CBE (31 October 2026) G & PHarma is active, legal situation “Normale toestand”, started on 18 January 2008.

Is G & PHarma registered on Peppol?

Yes, G & PHarma is registered on the Peppol network with ID 0208:0895026720.

What is the enterprise number of G & PHarma?

The enterprise number of G & PHarma is BE0895026720.

When was G & PHarma founded?

G & PHarma was founded on 18 January 2008.

Who are the directors of G & PHarma?

According to the 2025 annual accounts, the directors of G & PHarma are: Geertrui Put, Philippe Elens.

Is G & PHarma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 18 January 2008; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did G & PHarma make in 2025?

G & PHarma posted a profit after taxes of € 65,161 in financial year 2025.

What is the revenue of G & PHarma?

As a small company, G & PHarma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 275,713.

How much does an employee at G & PHarma earn?

The average wage cost per full-time employee at G & PHarma was € 67,100 in 2025: staff costs of € 140,895 for 2.1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does G & PHarma have?

According to the 2025 annual accounts, G & PHarma has 2.1 full-time equivalents (FTE).

G & PHarma (Private Limited) - Halen - BE0895026720

Dossier G & PHarma, printed on 31 October 2026 from databakkes.be/en/0895026720/g-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 15 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

G & PHarma from Halen, company number BE0895026720, closed financial year 2025 with a result of € 65,161 after tax. For that financial year G & PHarma recorded a gross margin of € 275,713 and equity of € 582,578. Compared with financial year 2024, the result moved from € 27,997 to € 65,161. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 16, 2026.

What it is worth Growing

€ 582,578

▲ 13% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 65,161

▲ 133% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 853

▼ 85% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 468,578.

People and assets in 2025

Full-time equivalents

2.1

▲ 0.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 140,895

▼ 1% vs 2024

€ 67,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 16,180

▼ 29% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 1 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 11,077

▼ 63% vs 2024

€ 7,740 is repaid this year. At this pace the long-term loan is gone in ≈ 1 years.

Owed to suppliers

€ 1,148

▼ 65% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 23,021

▼ 37% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 229,997 Gross margin 2022: € 229,997 First fiscal year in the series	€ 234,993 Gross margin 2023: € 234,993 ▲ 2% vs 2022 (€ 229,997) Favourable step	€ 232,677 Gross margin 2024: € 232,677 ▼ 1% vs 2023 (€ 234,993) Unfavourable step	€ 275,713 Gross margin 2025: € 275,713 ▲ 18% vs 2024 (€ 232,677) Favourable step	▲ 18%
Profit after taxes	€ 78,363 Profit after taxes 2022: € 78,363 First fiscal year in the series	€ 63,559 Profit after taxes 2023: € 63,559 ▼ 19% vs 2022 (€ 78,363) Unfavourable step	€ 27,997 Profit after taxes 2024: € 27,997 ▼ 56% vs 2023 (€ 63,559) Unfavourable step	€ 65,161 Profit after taxes 2025: € 65,161 ▲ 133% vs 2024 (€ 27,997) Favourable step	▲ 133%
Equity	€ 425,862 Equity 2022: € 425,862 First fiscal year in the series	€ 489,420 Equity 2023: € 489,420 ▲ 15% vs 2022 (€ 425,862) Favourable step	€ 517,418 Equity 2024: € 517,418 ▲ 6% vs 2023 (€ 489,420) Favourable step	€ 582,578 Equity 2025: € 582,578 ▲ 13% vs 2024 (€ 517,418) Favourable step	▲ 13%
Total debts	€ 694,685 Total debts 2022: € 694,685 First fiscal year in the series	€ 655,255 Total debts 2023: € 655,255 ▼ 6% vs 2022 (€ 694,685) Favourable step	€ 609,563 Total debts 2024: € 609,563 ▼ 7% vs 2023 (€ 655,255) Favourable step	€ 575,383 Total debts 2025: € 575,383 ▼ 6% vs 2024 (€ 609,563) Favourable step	▼ 6%
Cash	€ 2,517 Cash 2022: € 2,517 First fiscal year in the series	€ 1,215 Cash 2023: € 1,215 ▼ 52% vs 2022 (€ 2,517) Unfavourable step	€ 5,622 Cash 2024: € 5,622 ▲ € 4,407 vs 2023 (€ 1,215) Favourable step	€ 853 Cash 2025: € 853 ▼ 85% vs 2024 (€ 5,622) Unfavourable step	▼ 85%
Retained profit	€ 311,862 Retained profit 2022: € 311,862 First fiscal year in the series	€ 375,420 Retained profit 2023: € 375,420 ▲ 20% vs 2022 (€ 311,862) Favourable step	€ 403,418 Retained profit 2024: € 403,418 ▲ 7% vs 2023 (€ 375,420) Favourable step	€ 468,578 Retained profit 2025: € 468,578 ▲ 16% vs 2024 (€ 403,418) Favourable step	▲ 16%
Dividend	€ 92,000 Dividend 2022: € 92,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 92,000) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 141,735 Bank debt 2022: € 141,735 First fiscal year in the series	€ 101,579 Bank debt 2023: € 101,579 ▼ 28% vs 2022 (€ 141,735) Favourable step	€ 30,286 Bank debt 2024: € 30,286 ▼ 70% vs 2023 (€ 101,579) Favourable step	€ 11,077 Bank debt 2025: € 11,077 ▼ 63% vs 2024 (€ 30,286) Favourable step	▼ 63%
Balance sheet total	€ 1,120,546 Balance sheet total 2022: € 1,120,546 First fiscal year in the series	€ 1,144,675 Balance sheet total 2023: € 1,144,675 ▲ 2% vs 2022 (€ 1,120,546) Unchanged	€ 1,126,981 Balance sheet total 2024: € 1,126,981 ▼ 2% vs 2023 (€ 1,144,675) Unchanged	€ 1,157,961 Balance sheet total 2025: € 1,157,961 ▲ 3% vs 2024 (€ 1,126,981) Unchanged	▲ 3%
Employees (FTE)	1.7 Employees (FTE) 2022: 1.7 First fiscal year in the series	1.7 Employees (FTE) 2023: 1.7 Unchanged (1.7) Unchanged	2 Employees (FTE) 2024: 2 ▲ 0.3 vs 2023 (1.7) Unchanged	2.1 Employees (FTE) 2025: 2.1 ▲ 0.1 vs 2024 (2) Unchanged	▲ 0.1

Key figures of G & PHarma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to G & PHarma?

What happened at G & PHarma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 16, 2026 New annual accounts for financial year 2025: profit of € 65,161 (▲ 133% vs 2024). Source: NBB ↗
2023 Geertrui Put became a director. NBB
2023 Philippe Elens became a director. NBB
Jan 18, 2008 Start of the company according to the CBE. KBO
Jan 15, 2008 New establishment in Halen. KBO

In short

From € 78,363 profit in 2022 to € 65,161 profit in 2025.

Paid € 94,246 in corporate taxes since 2022.

Best year ever: 2022, with € 78,363 profit.

On average € 131,300 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Geertrui Put

Philippe Elens

G & PHarma

Apotheek Loksbergen BV 100%

Behind G & PHarma are Geertrui Put and Philippe Elens. It owns 100% of Apotheek Loksbergen BV itself.

Directors

According to the 2025 annual accounts

Geertrui Put

Director

Also active at: APOTHEEK LOKSBERGEN

since 2023

Philippe Elens

Director

since 2023

Establishments

Establishment units

Physical locations of this company

Registered office

Loksbergenstraat 61

3545 Halen

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

APOTHEEK LOKSBERGEN same network

€ 283,518 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0895.026.720

VAT number

BE 0895.026.720

Registered office

Loksbergenstraat 61, 3545 Halen

Names & denominations

G & PHarma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

18 January 2008

Peppol

Active · Active since 30 Aug 2025

Activities · NACE

Detailhandel in farmaceutische producten

Activiteiten van holdings

Holdings

View on CBE Public ↗ Annual accounts (NBB) ↗

G & PHarma

Warning lights

Financials

What happened to G & PHarma?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions